anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Many preterm very low birth weight infants require continuous positive airway pressure(CPAP) for breathing support because of lung immaturity. CPAP can be delivered by the infant flow(TM) device which is well studied. Prolonged use of nasal prongs CPAP has been shown to cause discomfort and, rarely, nasal injury leading to long term disfigurement. On the other hand, High flow nasal cannula (HFNC) ,which is another modality of delivering CPAP, creates less pressure on the nose and less disfiguring effect but previous research showed that the use of HFNC may be less effective than IF-CPAP in providing breathing support in these infants.

We plan to study 10 stable preterm infants born less than 32 weeks' gestation and 1.5 kilograms at birth after being stable for at least 48hours on IF-CPAP. babies will be randomized to start on IF-CPAP or HFNC for 30 minutes. After 45 minutes of adaptation, baby will be switched to the other modality for another 30 minutes. By inserting a specialized feeding tube with sensors into the stomach, we can measure the electrical activity of the diaphragm (EAdi). By analysing EAdi with each modality of delivering CPAP, we want to directly assess how HFNC affects breathing compared to IF-CPAP.
Bisoprolol (5 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
Participants (N=30) will be recruited across two churches, MorningStar Baptist Church and People's Baptist Church, to examine the feasibility and acceptability of the HAIL Online platform. Participants will complete the 8-week F\&S! exercise program (with access to the adjunct HAIL online platform), which will be delivered in-person as well as remote, and then continue to use the HAIL online platform during the 3-mo follow-up.
B- lines are a semiquantitative sign of extravascular lung water present in 1 out of 3 HF patients at rest and in 1 out of 2 during stress, and potentially useful for refining prognostic stratification and titrating diuretic therapy in these patients. We will enroll patients referred to SE with known or suspected HF, with either reduced or preserved ejection fraction. B-lines will be detected using the B-lines SE intervention. A sample size of about 2500 patients is required if the effect on mortality is evaluated.
1,133,557. Thionothiolcarbamic acid esters. FARBENFABRIKEN BAYER A.G. 27 June, 1967 [27 July, 1966], No. 29633/67. Heading C2C. [Also in Division A5] The invention comprises thionothiolcarbamic acid esters of the formula in which R denotes a hydrogen atom or an alkyl radical of 1-4 carbon atoms, X denotes a hydrogen atom and/or one or more halogen atoms and/or one or more alkyl radicals of 1-4 carbon atoms, and R 1  and R 2  denote identical or different, straight- or branchedchain, alkyl radicals of 1-4 carbon atoms or, together with the nitrogen atom, form a 5- or 6-membered heterocyclic ring, optionally containing a further nitrogen atom or an oxygen or sulphur atom. The compounds may be prepared by reaction of a benzoic ester of the formula in which Hal denotes a halogen atom, with a thionothiolcarbamic acid salt of the formula in which Me denotes a univalent metal atom or ion or an ammonium ion. Preferred reaction conditions are described, and examples are given. The products are useful as acaricides and fungicides (see Division A5).
This is a single-site, randomized (participants are assigned to treatment by chance), double-blind study (neither physician nor participant knows whether the participant is receiving active treatment or placebo). Placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect. This study consists of two parts (part 1, single dosing and part 2, multiple dosing). Part 1: An alternating panel design will be used, whereby the first panel of 9 participants will receive the first, third, and fifth administered doses, while the second panel of 9 participants will receive the second, fourth, and sixth administered doses.Up to 2 additional dosings (1 per panel) may be evaluated to further understand the study drug. For each dose administration, 6 participants will be assigned to active treatment and 3 to placebo. Each participant will receive JNJ-42165279 on 2 occasions and placebo once during the first 3 dosings. The planned doses of JNJ-42165279 range from 2.5 to 500 mg. The sponsor and investigator will review blinded data associated with each dose prior to administration of the next dose. Participants will check into the study center the morning prior to each dosing (Day -1) and will remain at the center until discharge 72 hours after dosing (Day 4). Participants will be dosed approximately every 4 weeks. Part 2: A separate cohort of 9 healthy male volunteers will receive repeated daily dosing of 100 mg JNJ-42165279 or placebo (6 participants will receive JNJ-42165279 and 3 participants will receive placebo) for 6 consecutive days. Participants will check into the study center the morning prior to their first dosing (Day -1) and will remain at the center until discharge 72 hours after receiving their last dose on Day 6. Participants in Part 1 and 2 will return for a follow-up visit 7 to 14 days after their final discharge from the study center.
Techniques for detecting a possible health issue in a user are described. Data related to social media activity for a user is received over a communications network from one or more computing devices. A user analysis profile is generated for the user using a first machine learning model. The user analysis profile includes a personality profile and a mood score. A weighted score associated with potential health issues for the user is determined by classifying the user analysis profile using a second machine learning model. The weighted score exceeds a pre-determined threshold, and electronic notification is provided to a pre-designated person regarding the potential health issue.
The present invention provides methods for enhancing or inducing airway epithelial repair and/or regeneration and/or for the normalization of airway epithelial remodeling, using local deposition of one or more pro-regenerative factors, preferably a peptide or protein from the trefoil family factor (TFF) family. The pro-regenerative factor is administered to a patient as a treatment of Chronic obstructive pulmonary disease (COPD), chronic bronchitis, Cystic fibrosis, Asthma, Bronchiectasis, Panbronchiolitis, pneumonia, ventilator associated pneumonia (VAP), hospital acquired pneumonia (HAP), community acquired pneumonia (CAP), severe community acquired pneumonia (sCAP) and pneumocystis carinii or to patients suffering from lung damage reducing the function of the mucociliary transport system based on fully functioning cilia secondary to, e.g. inhalation of toxic fumes. The present invention also provide therapy and or prophylactic or preemptive, i.e.prophylaxis based on a predefined group of patients like intervention in smokers in order to enhance ongoing airway epithelial repair and/or regeneration of the airways cilia improving the mucociliary clearance. The pro-regenerative factor is administered intratracheal, intrabronchial, intraalveolar or broncioalveolar. Administration for example via inhalation of an aerosol or as a dry powder and/or administered as a bronchoalveolar lavage (BAL) an effective amount of the agent.
A web-based system configured to interact with users of mechanical exercise equipment is provided. The system includes a sensor configured to transform repetitive actions from a mechanical apparatus, such as an exercise machine, into electrical signals or switch closures. A count recorder communicates with the sensor to obtain the data. A computing device receives the data from the count recorder and converts and processes the data into measurable data content. A remote application server is accessible by a plurality of computing devices and is operable to communicate with the computing devices through a web-based application. The web-based application can receive and display the data set through the local computing device. The data set is viewable by one or more users through the web-based application. The web-based application allows for users of the application to view other user's activity in near real-time.
PURPOSE:To obtain the subject ceramic material having excellent persistency of drug action and suitable for the prevention of infection and the remedy of affected part by putting a phospholipid and a drug in a hole or a through hole bored in a bioceramic material having dense texture. CONSTITUTION:A hole and/or a through hole are bored in a bioceramic material (preferably calcium phosphate ceramics or alumina) having dense texture and a porosity of about <=3% and harmless to living body. A liposome-forming phospholipid and a drug are held in at least one of the hole and the through- hole. The cross-sectional area of the hole and the through-hole is preferably 0.006-0.05cm<2>. When the ceramic material is brought into contact with body fluid, a liposome including the drug is formed and the drug is released from the liposome into the hole, etc., without changing the physical and chemical properties. Accordingly, the release of the drug can be retarded.
In neurovascular disease, and stroke in particular, physicians often want to be able to detect regions of ischemia in the brain and the recanalization status of cerebral blood vessels. Perfusion and collateral vessel imaging is a possible approach for doing this. These imaging techniques are able to differentiate ischemic core in parenchymal tissue in the brain versus salvageable penumbra tissue around the core. Also the recanalization status of blood vessels can be evaluated using this technique. This study wishes to investigate if the x-ray C-arm in the treatment room can generate perfusion and collateral images of clinical value during treatment, using a technique known as C-arm computed tomography. If this study shows that to be the case, then it might be feasible in the future to bypass CT or MR perfusion/collateral imaging for some patients when they arrive at the hospital, since all this imaging can be done in the treatment room. In the future, this imaging approach may have the potential to simplify and improve patient workflows and reduce the time between hospital arrival and treatment for these patients and could also potentially compensate for missing imaging information.
Subjects enrolled in this arm had non-erosive reflux disease with reflux (heartburn) for at least 6 of the preceding 12 months. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
A total of 1261 patients with type 2 diabetes inadequately controlled on basal insulin alone or basal insulin in combination with oral drugs participated in a randomized, double-blind placebo-controlled trial designed to evaluate the efficacy of linagliptin as add-on therapy to basal insulin over 24 weeks. Randomization was stratified by baseline HbA1c (<8.5% vs ≥8.5%), renal function impairment status (based on baseline eGFR), and concomitant use of oral antidiabetic drugs (none, metformin only, pioglitazone only, metformin + pioglitazone). Patients with a baseline A1C of >7% and <10% were included in the study including 709 patients with renal impairment (eGFR <90 mL/min), most of whom (n=575) were categorized as mild renal impairment (eGFR 60 to <90 mL/min). Patients entered a 2-week placebo run-in period on basal insulin (e.g., insulin glargine, insulin detemir, or NPH insulin) with or without metformin and/or pioglitazone background therapy. Following the run-in period, patients with inadequate glycemic control were randomized to the addition of either 5 mg of linagliptin or placebo, administered once daily. Patients were maintained on a stable dose of insulin prior to enrollment, during the run-in period, and during the first 24 weeks of treatment. Patients who failed to meet specific glycemic goals during the double-blind treatment period were rescued by increasing background insulin dose. 

Linagliptin used in combination with insulin (with or without metformin and/or pioglitazone), provided statistically significant improvements in A1C and FPG compared to placebo (Table 11) after 24 weeks of treatment. The mean total daily insulin dose at baseline was 42 units for patients treated with linagliptin and 40 units for patients treated with placebo. Background baseline diabetes therapy included use of: insulin alone (16.1%), insulin combined with metformin only (75.5%), insulin combined with metformin and pioglitazone (7.4%), and insulin combined with pioglitazone only (1%). The mean change from baseline to Week 24 in the daily dose of insulin was +1.3 IU in the placebo group and +0.6 IU in the linagliptin group. The mean change in body weight from baseline to Week 24 was similar in the two treatment groups. The rate of hypoglycemia, defined as all symptomatic or asymptomatic episodes with a self measured blood glucose was also similar in both groups (21.4% linagliptin; 22.9% placebo) in the first 24 weeks of the study.

The difference between treatment with linagliptin and placebo in terms of adjusted mean change from baseline in HbA1c after 24 weeks was comparable for patients with no renal impairment (eGRF ≥90 mL/min, n=539), with mild renal impairment (eGFR 60 to <90 mL/min, n=565), or with moderate renal impairment (eGFR 30 to <60 mL/min, n=124).
The invention relates to a tumor photo-thermal excision device based on the X-ray heating technology and belongs to the technical field of medical detection. The tumor photo-thermal excision device comprises an X-ray thermal radiator. The X-ray thermal radiator comprises an X-ray heating particle, a temperature-sensitive X-ray luminous particle and an amino-modified silicon dioxide shell layer. The amino-modified silicon dioxide shell layer covers the temperature-sensitive X-ray luminous particle and the X-ray heating particle. Or, the amino-modified silicon dioxide shell layer covers the temperature-sensitive X-ray luminous particle and the temperature-sensitive X-ray luminous particle covers the X-ray heating particle. The tumor photo-thermal excision device based on the X-ray heating technology has the advantage of killing tumor cells without damaging ordinary cells.
OBJECTIVES: This report presents descriptive data on the demographic and audiological characteristics of US adults with perceived mild-to-moderate hearing loss, the primary candidates for over-the-counter (OTC) hearing aids.
DESIGN: The analyses are descriptive and present population-weighted responses for various self-reported demographic and audiological variables for adults with mild or moderate perceived hearing trouble. Results of pure-tone audiometry and immittance measures are also presented. Nationally representative datasets from the National Health and Nutrition Examination Surveys (NHANES) for 2011 to 2012, 2015 to 2016, and 2017 to 2020, the three most recent NHANES datasets with audiological information, were used.
RESULTS: The NHANES datasets indicated that there are 49.5 million adults in the United States with perceived mild-to-moderate hearing trouble. Results indicated that OTC hearing-aid candidates are most frequently 50 to 69 years of age, married, and identify as non-Hispanic White race/ethnicity. Most of these individuals graduated from high school, had several risk factors for hearing loss, had not had a hearing test in the past 5 years, and had never used hearing aids or assistive listening devices previously. The typical audiometric profile was a bilaterally symmetrical sloping hearing loss with slight to mild hearing loss above 2000 Hz. Group data showed normal immittance measures and absence of otoscopic abnormalities except for the presence of excessive (not impacted) cerumen in about 13% of the OTC hearing-aid candidates.
CONCLUSIONS: Tens of millions of US adults have perceived mild-to-moderate hearing trouble but have not pursued assistance, either through obtaining a hearing test or acquiring prescription hearing aids.
Chronic kidney disease(CKD) is an insidious disease that has become a significant global public health issue due to its high incidence rate, low awareness, low diagnostic rate, poor prognosis, and high medical costs. Recent studies have shown that CKD development is associated with varying degrees of ferroptosis features. Traditional Chinese medicine(TCM) can regulate iron metabolism, lipid peroxidation, antioxidant systems to inhibit ferroptosis and delay the progression of CKD. Consequently, the intervention mechanism of ferroptosis has become one of the focuses of CKD research. TCM has thousands of years of traditional experience and wisdom. It focuses on the overall regulation of human body functions and can stimulate the body's disease resistance and recovery capabilities, which has certain advantages in treating CKD. However, there is currently a lack of comprehensive articles on the application of TCM in intervening ferroptosis to treat CKD and the pathogenesis of ferroptosis in CKD. Therefore, this article summarizes the latest research progress both domestically and internationally, briefly introduces the main mechanisms of ferroptosis, and systematically reviews the relationship between ferroptosis and CKD. The article integrates TCM theories related to ferroptosis in CKD, including "deficiency" "stasis" "phlegm turbidity" and "toxins" and summarizes the research status of active ingredients and herbal formulas in intervening ferroptosis to treat CKD. By considering ferroptosis from a new perspective, this article aims to provide new targets and directions for the application of TCM in treating CKD.
BACKGROUND Atrial flutter is associated with significant morbidity and mortality. Standard treatment involves rate and rhythm control medications, with ablation procedures reserved for more persistent cases. While ablation is generally successful, it carries risks, such as complete heart block, as in this case. CASE REPORT A 73-year-old woman presented for ablation of recurrent atypical atrial flutter. Electro-anatomic mapping demonstrated counterclockwise mitral annular flutter. An anterior ablation line was initially created from the right superior pulmonary vein to the mitral valve annulus. As the line was extended to the anterior mitral valve annulus at the 9 o'clock position, complete heart block occurred, and ablation was immediately terminated. Complete recovery of atrioventricular (AV) conduction occurred within 1 min. The catheter tip was within 1.8 cm from the His bundle, as denoted by the yellow tag on the CARTO map. A second mitral line was created anteriorly at the 11 o'clock position on the mitral valve annulus and extended to the left atrial roof line, with the termination and creation of a bi-directional mitral isthmus block. She remained in sinus rhythm after ablation, with PR prolongation and no AV block. The following day, she developed severe bradycardia due to complete heart block, with a slow ventricular escape rhythm, requiring implantation of a permanent pacemaker. CONCLUSIONS This case underscores the importance of precise catheter positioning during anterior mitral line ablation to prevent complications, such as AV block. Anterior mitral line ablation should be performed in a more anterior location away from the septum to minimize the risk of AV block.
PURPOSE:The titled cellular surface antigen recognition type antibody, produced by a hybridoma prepared by using a cellular strain (MKN-45) derived from a gastric low differentiation type gladular cancer as an immunization source, having a light chain of IgG1(K) and capable of exhibiting positive reaction to cancer cells, e.g. specific gastric cancer or esophageal cancer. CONSTITUTION:A monoclonal antibody obtained by fractionating a cell extract of an established cell (MKN-45) derived from a gastric low differentiation type glandular cancer, mixing the resultant high-molecular fraction having 700,000-1,500,000mol.wt. with complete Freund's adjuvant, immunizing an animal, e.g. mouse, with the resultant mixture, collecting a cell producing an antibody, carrying out cell fusion with a myelomatous cell of an animal of the same species, cloning the resultant cell to give a cloned hybridoma, transplanting the resultant cloned hybridoma to the abdominal cavity of an animal, e.g. BALB/C mouse, to produce the aimed antibody capable of exhibiting positive reaction to cancer cells of gastric cancer (MKN-45 or KATO-III), esophageal cancer (TE-3), lung cancer (PC-10) and colonic cancer (Colo201) and recovering and purifying the antibody from the ascites.
Study participants who were enrolled and received treatment with low dose JNJ-81201887 in parent clinical studies (81201887MDG2001 \[NCT05811351\]; 81201887MDG1003) will enter this long-term extension (LTE) study. No study intervention will be administered as part of this study.
The invention discloses a high-zinc and low-sodium vitamin C effervescent tablet and a preparation method thereof. The effervescent tablet comprises the following main components in percentage by weight: 3-50% of vitamin C, 10-50% of anhydrous citric acid, 1-50% of zinc carbonate, 0.1-30% of sodium hydrogen carbonate, 0.1-15% of PEG6000, 0.1-15% of essence, 0.1-15% of stevioside and 0.1-15% of saccharose. The high-zinc and low-sodium vitamin C effervescent tablet disclosed by the invention has moderate sour and sweet taste. Vitamin C in the effervescent tablet has the effects of supplementing nutrition and improving the immunity, and zinc of zinc ions released after zinc carbonate effervesces is a biological element of a human body. A part of sodium hydrogen carbonate or sodium carbonate is replaced by zinc carbonate, so that the problem that excessive sodium intake by the human body is probably caused by taking effervescent tablet is solved. The sodium intake of the human body can be reduced, and diseases such as hypertension, kidney diseases, cardiovascular and cerebrovascular diseases and the like are avoided.
BACKGROUND: Tobacco smoking is an independent risk factor for chronic kidney disease (CKD) and increases morbidity and mortality in CKD patients. The primary objective of the study was to investigate the epidemiology of smoking in patients undergoing maintenance dialysis in France. A second objective was to assess the involvement of nephrologists in supporting patients for smoking cessation.
METHODS: Data on the smoking history of prevalent patients on maintenance dialysis in France between 2010 and 2020 were obtained from the REIN database (Renal Epidemiology and Information Network), updated by all French nephrology and dialysis centers. As for the support to smoking discontinuation, a questionnaire on smoking cessation assistance was sent to all members of the French Society of Nephrology, Dialysis and Transplantation (SFNDT).
RESULTS: The proportion of current smokers among patients on maintenance dialysis was 10.4% in 2010, 11.2% in 2015 and 11.6% in 2020. A total of 228 nephrologists among the 790 members of the SFNDT participated in the survey (28.9%). Most respondents were women (57.3%), worked at a public hospital (61.1%), were under 40 years of age (51.3%) and had no history of smoking (60.8%). The majority reported asking patients about their smoking status and offering brief advice. Among respondents, 72.8% offered help with smoking cessation, 46.3% referred their smoking patients to a tobacco specialist, 51.8% reported prescribing drugs to quit tobacco, and 81.6% requested further training in how to support patients for smoking cessation.
CONCLUSION: Smoking cessation training for nephrologists and dedicated programs for patients in nephrology units could improve our practices and decrease the high prevalence of smoking in patients with ESKD.